Log In
Print
BCIQ
Print
Print this Print this
 

Plegridy (Peginterferon beta-1a) (BIIB017)

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionPegylated interferon (IFN) beta-1a
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat relapsing forms of multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation U.S. - Fast Track (Treat relapsing-remitting multiple sclerosis (RRMS));
U.S. - Undisclosed Review (Treat relapsing-remitting multiple sclerosis (RRMS));
EU - Standard Review (Treat relapsing-remitting multiple sclerosis (RRMS))
Partner UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$2.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today